Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have received an average recommendation of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $56.38.

A number of research analysts have issued reports on IMCR shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research report on Monday, July 13th. Mizuho raised their price target on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. JPMorgan Chase & Co. began coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Finally, TD Cowen upgraded shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th.

Immunocore Stock Performance

Shares of NASDAQ IMCR opened at $30.72 on Tuesday. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The stock has a 50 day simple moving average of $34.44 and a 200-day simple moving average of $31.76. The company has a market cap of $1.58 billion, a PE ratio of -83.02 and a beta of 0.74. Immunocore has a 12-month low of $27.56 and a 12-month high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, equities research analysts forecast that Immunocore will post 0.06 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Braidwell LP bought a new stake in Immunocore during the second quarter worth approximately $16,552,000. Armistice Capital LLC boosted its stake in Immunocore by 33.3% during the 4th quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock valued at $38,112,000 after purchasing an additional 274,000 shares in the last quarter. Fiera Capital Corp boosted its stake in Immunocore by 31.4% during the 4th quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock valued at $36,266,000 after purchasing an additional 249,674 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Immunocore by 30.9% during the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock valued at $17,919,000 after purchasing an additional 140,308 shares during the period. Finally, Rhenman & Partners Asset Management AB increased its position in shares of Immunocore by 442.0% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 153,278 shares of the company’s stock valued at $5,320,000 after purchasing an additional 125,000 shares during the period. 84.50% of the stock is currently owned by institutional investors.

About Immunocore

Immunocore Holdings plc is a biotechnology company that develops T-cell receptor (TCR) therapies designed to direct the immune system against cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-related peptides presented on the surface of cells and recruit T cells to destroy targeted cells.

The company’s lead product is KIMMTRAK (tebentafusp-tebn), an ImmTAC therapy approved in the United States, European Union and other markets for the treatment of unresectable or metastatic uveal melanoma in certain patients.